Novo Nordisk (NVO) is scheduled to announce Q4 2022 earnings on Wednesday, 01 February 2023, before market open. Wallstreet estimates an EPS of $0.84 and a revenue of $6.81 B in the upcoming results. Historically, Novo Nordisk beated EPS estimates 60% of the times.
About Novo Nordisk
Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.